The paper “Sunitinib Malate in the Treatment of Renal Cell Carcinoma and Gastrointestinal Stromal Tumor: Recommendations for Patient Management” summarizes published literature relating to the tolerability of sunitinib malate and provides recommendations for patient assessments and management.
Tolerability of sunitinib is generally high. More common side effects include lethargy, diarrhea, and hypertension. Side effects seldom lead to treatment discontinuation. Other more troublesome, but largely uncommon, side effects include hypothyroidism and hematological toxicity.
Sunitinib is an effective treatment for RCC and GIST. Supportive measures such as concomitant medications can usually manage mild to moderate toxicities, without need to reduce or disrupt the administration of sunitinib. In case of severe toxicities, interruption of treatment until patient has returned to normal or mild level is recommended.
According to researchers, it is likely that sunitinib may be effective in other cancers or in combination with other therapies.
___________________________________________________
This paper is published in the December 2007 issue of Asia-Pacific Journal of Clinical Oncology - the abstract is available free online at http://www.blackwell-
Media wishing to receive a PDF or schedule media interviews with the author should contact Alina Boey, PR & Communications Manager at alina.boey@asia.blackwellpublishing.com or phone 613-83591046.
Asia-Pacific Journal of Clinical Oncology
The Asia-Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia Pacific region in relation to cancer treatment and care. The Journal publishes pre-clinical studies, translational research, clinical trials and epidemiological studies, describing new findings of clinical significance. Clinical studies, particularly prospectively designed clinical trials, are encouraged.
About Wiley-Blackwell
Wiley-Blackwell was formed in February 2007 as a result of the merger between Blackwell Publishing Ltd. and Wiley’s Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit www.blackwellpublishing.com or http://interscience.wiley.com.
About Wiley
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for 200 years, helping people around the world meet their needs and fulfill their aspirations. Since 1901, Wiley and its acquired companies have published the works of more than 350 Nobel laureates in all categories: Literature, Economics, Physiology/Medicine, Chemistry and Peace.
Our core businesses include scientific, technical, medical and scholarly journals, encyclopedias, books, and online products and services; professional/
